FDA public meeting
This article was originally published in The Tan Sheet
Executive Summary
FDA will hold a public meeting Feb. 7 to discuss potential revisions of chemistry, manufacturing and controls supplement regulations, the agency announces Jan. 5. "FDA is evaluating how it could revise its regulations to allow for consideration of risk-based approaches based on manufacturing process understanding, including prior-knowledge of similar products, and overall quality systems to provide an enhanced risk-based approach to the regulatory process, which would reduce the number of supplements," FDA writes. The agency is "considering redefining what FDA considers to be a major manufacturing change, reducing the reporting burden for certain changes, and creating a new reporting category of manufacturing changes that would not require notification to FDA." The decision is in line with FDA's Pharmaceutical Current Good Manufacturing Practices for the 21st Century Initiative (1"The Tan Sheet" July 3, 2006, p. 6). Comments should be submitted March 7...
You may also be interested in...
Industry Input Will Bolster Risk-Based Inspection Approach – FDA’s Ellsworth
FDA is "hoping" to use future facility inspections to compile data that will strengthen the "process risk" prong of its risk-based site selection model by gaining knowledge about quality systems currently in use by industry, according to New Jersey District Director Douglas Ellsworth
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.